H.C. Wainwright raised the firm’s price target on Longboard Pharmaceuticals to $60 from $25 and keeps a Buy rating on the shares. The analyst says bexicaserin demonstrated differentiated clinical and commercial profile, emerging as potential blockbuster epilepsy drug.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LBPH:
- Longboard Pharmaceuticals 10M share Secondary priced at $21.00
- Longboard Pharmaceuticals prices 10M share secondary at $21, Bloomberg says
- Longboard Pharmaceuticals announces $150M common stock offering
- Longboard price target raised to $46 from $25 at Evercore ISI
- Longboard Pharmaceuticals price target raised to $32 from $16 at Guggenheim